Why the study?
Clinical follow-up and remote management of chronic heart failure are highly variable and poorly effective, creating a need for new remote management strategies to maintain clinical stability and prevent hospitalizations.
Does haemodynamic guided heart failure management using a PA pressure sensor improve safety and reduce HF hospitalizations in patients with NYHA Class III symptoms and prior HF hospitalization?
Does haemodynamic guided heart failure management using a PA pressure sensor improve safety and reduce HF hospitalizations in patients with NYHA Class III symptoms and prior HF hospitalization?
Answers are grounded in this paper and cite their sources.
The COAST study will investigate the generalizability, safety, and efficacy of remote haemodynamic guided HF management using the CardioMEMS device in a multinational setting.
AIMS: Chronic heart failure reduces quality and quantity of life and is expensive for healthcare systems. Medical treatment relies on guideline-directed therapy, but clinical follow-up and remote management is highly variable and poorly effective. New remote management strategies are needed to maintain clinical stability and avoid hospitalizations for acute decompensation. METHODS AND RESULTS: The CardioMEMS Post-Market Study is a prospective, international, single-arm, multicentre, open-label study (NCT02954341) designed to examine the feasibility of haemodynamic guided heart failure management using a small pressure sensor permanently implanted in the pulmonary artery (PA). Daily uploaded PA pressures will be reviewed weekly to remotely guide medical management of patients with persistent NYHA Class III symptoms at baseline and a hospitalization in the prior 12 months. The study will enrol up to 800 patients from 85 sites across the United Kingdom, Europe, and Australia. The primary safety endpoint will assess device or system-related complications or sensor failures after 2 years of follow-up. Efficacy will be estimated after 1 year of follow-up comparing HF hospitalization rates before and after sensor implantation. Observational endpoints will include mortality, patient, and investigator monitoring compliance, PA pressure changes, quality of life, and several pre-defined subgroup analyses. CONCLUSIONS: The CardioMEMS Post-Market Study will investigate the generalizability of remote haemodynamic guided HF management in a number of national settings. The results may support the more widespread implementation of this novel clinical management approach.
No takes yet. Share an insight, caveat, or question.
Cowie et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: